Business
Equity Fundraising raises £3.5 million
EDX Medical Group plc has successfully raised £3.5 million through an equity fundraising, issuing 24,999,999 new ordinary shares at 14p each to existing high net worth shareholders. The net proceeds will accelerate the company's prostate cancer programme, focusing on developing diagnostic products and services. This follows a previous funding round in October 2025 which secured up to £4 million. Following this latest fundraising, the company's total voting rights will be 411,594,583 ordinary shares. Disclaimer*
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n\nFebruary 16, 2026\nEDX Medical Group plc\nAQSE: EDX\n(\"EDX Medical\" or \"the Company\")\n \nEquity Fundraising raises £3.5 million\nCAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces that the board of the Company has approved the issue of 24,999,999 new ordinary shares of 1p each in the Company (the \"Subscription Shares\") at a price of 14p per share (the \"Fundraising\") raising £3,500,000 for the Company.\nExisting high net worth shareholders have subscribed to the Fundraising. \nThe net proceeds of the Fundraising will support the acceleration of the Company's prostate cancer programme which involves the development and delivery of best-in-class diagnostic products and services.\nApplication has been made for the Subscription Shares to be admitted to trading on the AQSE Growth Market (\"Admission\") and the Subscription remains conditional on Admission. It is expected that Admission will take place on Friday, February 20, 2026.\nThis latest fundraising follows the Company's announcement on October 20, 2025 that the Company secured up to £4 million funding for product development and commercial operations through a combination of the issue of 14,285,713 new ordinary shares of 1p each in the Company at a price of 14p per share to raise £2.0 million as well as the issue of a new convertible loan note (CLN) agreement for up to £2.0 million to Professor Sir Chris Evans, the Company's founder and Chief Scientific Officer.\nProfessor Sir Chris Evans, OBE, founder of EDX Medical, commented: \"We are delighted that investors in the Company have once again reinforced their support for the work we are doing to provide game-changing diagnostic solutions for the early detection of prostate cancer. The need for innovation in this ar...